GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (STU:6BG) » Definitions » Gross-Profit-to-Asset %

Lytix Biopharma AS (STU:6BG) Gross-Profit-to-Asset % : 1.48% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lytix Biopharma AS's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.13 Mil. Lytix Biopharma AS's average Total Assets over the quarter that ended in Dec. 2024 was €8.62 Mil. Therefore, Lytix Biopharma AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 1.48%.


Lytix Biopharma AS Gross-Profit-to-Asset % Historical Data

The historical data trend for Lytix Biopharma AS's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS Gross-Profit-to-Asset % Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - 16.49 6.08 3.44 10.52

Lytix Biopharma AS Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 77.04 - 1.38 1.48

Competitive Comparison of Lytix Biopharma AS's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lytix Biopharma AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lytix Biopharma AS's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's Gross-Profit-to-Asset % falls into.


;
;

Lytix Biopharma AS Gross-Profit-to-Asset % Calculation

Lytix Biopharma AS's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0.948/( (5.552+12.472)/ 2 )
=0.948/9.012
=10.52 %

Lytix Biopharma AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.128/( (4.774+12.472)/ 2 )
=0.128/8.623
=1.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Lytix Biopharma AS Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lytix Biopharma AS Business Description

Traded in Other Exchanges
Address
Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines